NKMAX Co., Ltd. Logo

NKMAX Co., Ltd.

Biotech firm for NK cell therapies, global research reagents, diagnostics, and supplements.

182400 | KO

Overview

Corporate Details

ISIN(s):
KR7182400002
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 돌마로 172 정자동, 헬스케어혁신파크 1층및6층, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NKMAX Co., Ltd. is a biotechnology company specializing in technologies centered on Natural Killer (NK) cells. The company's operations span multiple segments, including the development of NK cell-based immunotherapies for cancer and other diseases. It is a key global manufacturer and supplier of high-quality research reagents, providing recombinant proteins and monoclonal antibodies to over 2,000 research institutions and diagnostic firms worldwide. Additionally, NKMAX offers a precision diagnostic test to quantify NK cell activity for immune function assessment and markets a line of dietary supplements, such as NK365, designed to support the immune system.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-04 00:00
Legal Proceedings Report
회생절차종결결정
Korean 8.5 KB
2025-09-03 00:00
Regulatory News Service
기타시장안내 (실질심사 대상여부 결정을 위한 조사기간 연장 안내 )
Korean 3.2 KB
2025-08-25 00:00
Legal Proceedings Report
회생절차종결신청
Korean 12.4 KB
2025-08-14 00:00
Board/Management Information
대표이사변경
Korean 10.4 KB
2025-08-14 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 13.7 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-08-14 00:00
Audit Report / Information
반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Korean 13.6 KB
2025-08-13 00:00
Delisting Announcement
기타시장안내 (상장적격성 실질심사 대상결정 기한 안내)
Korean 3.1 KB
2025-08-12 00:00
Audit Report / Information
[기재정정]감사보고서제출 (2024사업연도)
Korean 45.4 KB
2025-08-12 00:00
Audit Report / Information
[기재정정]감사보고서제출 (2023사업연도)
Korean 29.1 KB
2025-08-12 00:00
Regulatory News Service
기타주요경영사항 (자본전액잠식등 사유 해소자료 제출)
Korean 3.6 KB
2025-08-12 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.9 MB
2025-08-12 00:00
Delisting Announcement
기타시장안내 (감사의견 관련 형식적 상장폐지 사유 해소 및 매매거래정지 지속 안내)
Korean 7.0 KB
2025-08-12 00:00
Delisting Announcement
주권매매거래정지기간변경 (상장폐지 사유 해소)
Korean 5.0 KB
2025-08-12 00:00
Audit Report / Information
[기재정정]사업보고서 (2024.12)
Korean 623.6 KB

Automate Your Workflow. Get a real-time feed of all NKMAX Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NKMAX Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NKMAX Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America
APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea
397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060

Talk to a Data Expert

Have a question? We'll get back to you promptly.